Vimarsana
Biggest News Aggregation in the World

Page 40 - Analyst Day News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Analyst Day. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Analyst Day Today - Breaking & Trending Today

Thermo Fisher Scientific (TMO) Q3 2023 Earnings Call Transcript - Vimarsana News

Thermo Fisher Scientific (TMO) Q3 2023 Earnings Call Transcript

TMO earnings call for the period ending September 30, 2023.

Source: fool.com
Cytokinetics Provides Update on Cardiac Myosin Inhibitor Programs and Plans to Build a Specialty Cardiology Franchise at Virtual Investor & Analyst Day - Vimarsana News

Cytokinetics Provides Update on Cardiac Myosin Inhibitor Programs and Plans to Build a Specialty Cardiology Franchise at Virtual Investor & Analyst Day

New Long-Term Data from FOREST-HCM, the Open-Label Extension Study of Aficamten,Show Sustained Improvements in Clinical Efficacy Endpointsand No Treatment Interruptions for Low Ejection Fraction ...

Johnson & Johnson (NYSE:JNJ) Q3 2023 Earnings Call Transcript - Vimarsana News

Johnson & Johnson (NYSE:JNJ) Q3 2023 Earnings Call Transcript

Johnson & Johnson (NYSE:JNJ) Q3 2023 Earnings Call Transcript October 17, 2023 Operator: Good morning, and welcome to Johnson & Johnson’s Third Quarter 2023 Earnings Conference Call. All participants will be in a listen-only mode until the question-and-answer session of the conference. This call is being recorded. If anyone has any objections, you may disconnect […]

Source: yahoo.com
Johnson & Johnson (JNJ) Q3 2023 Earnings Call Transcript - Vimarsana News

Johnson & Johnson (JNJ) Q3 2023 Earnings Call Transcript

JNJ earnings call for the period ending September 30, 2023.

Source: fool.com
Ultragenyx Announces Program and Pipeline Updates at Analyst Day Including Interim Data from ... - Vimarsana News

Ultragenyx Announces Program and Pipeline Updates at Analyst Day Including Interim Data from ...

Treatment with setrusumab (UX143) for at least 6 months resulted in 67% reduction in annualized fracture rate in patients with OI in Phase 2/3 Orbit study